These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 19366571)

  • 41. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
    Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
    Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.
    Beckmann C; Brittnacher M; Ernst R; Mayer-Hamblett N; Miller SI; Burns JL
    Infect Immun; 2005 Jan; 73(1):444-52. PubMed ID: 15618183
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Ratjen F; Walter H; Haug M; Meisner C; Grasemann H; Döring G
    Pediatr Pulmonol; 2007 Mar; 42(3):249-55. PubMed ID: 17243185
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine.
    Ahmadi H; Tabaraie B; Maleknia S; Pormirzagholi F; Nejati M; Hedayati MH
    J Infect Dev Ctries; 2012 Oct; 6(10):721-6. PubMed ID: 23103894
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae.
    Bertot GM; Becker PD; Guzmán CA; Grinstein S
    J Infect Dis; 2004 Apr; 189(7):1304-12. PubMed ID: 15031801
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mucosal immunization with polyamine transport protein D (PotD) protects mice against nasopharyngeal colonization with Streptococcus pneumoniae.
    Shah P; Briles DE; King J; Hale Y; Swiatlo E
    Exp Biol Med (Maywood); 2009 Apr; 234(4):403-9. PubMed ID: 19176871
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunization with Bivalent Flagellin Protects Mice against Fatal
    Behrouz B; Hashemi FB; Fatemi MJ; Naghavi S; Irajian G; Halabian R; Imani Fooladi AA
    J Immunol Res; 2017; 2017():5689709. PubMed ID: 29201922
    [No Abstract]   [Full Text] [Related]  

  • 48. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa.
    Ding B; von Specht BU; Li Y
    Vaccine; 2010 Jun; 28(25):4119-22. PubMed ID: 20433804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [[Vaccine development for P. aeruginosa: based on antigen cloning of clinical vaccines][].
    von Specht BU
    Zentralbl Chir; 1999; 124(4):298-302. PubMed ID: 10355084
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of beta-defensin-1 gene polymorphisms with Pseudomonas aeruginosa airway colonization in cystic fibrosis.
    Tesse R; Cardinale F; Santostasi T; Polizzi A; Manca A; Mappa L; Iacoviello G; De Robertis F; Logrillo VP; Armenio L
    Genes Immun; 2008 Jan; 9(1):57-60. PubMed ID: 17960157
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pseudomonas aeruginosa and Burkholderia cenocepacia infections in patients affected by cystic fibrosis: serum resistance and antibody response.
    Savoia D; Deplano C; Zucca M
    Immunol Invest; 2008; 37(1):19-27. PubMed ID: 18214797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity.
    Heurtault B; Gentine P; Thomann JS; Baehr C; Frisch B; Pons F
    Pharm Res; 2009 Feb; 26(2):276-85. PubMed ID: 18781377
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.
    Kamei A; Coutinho-Sledge YS; Goldberg JB; Priebe GP; Pier GB
    Infect Immun; 2011 Mar; 79(3):1289-99. PubMed ID: 21149583
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Local IgA and IgG response to intratracheal immunization with Pseudomonas aeruginosa antigens.
    Johansen HK; Høiby N
    APMIS; 1992 Jan; 100(1):87-90. PubMed ID: 1536724
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.
    Cripps AW; Peek K; Dunkley M; Vento K; Marjason JK; McIntyre ME; Sizer P; Croft D; Sedlak-Weinstein L
    Infect Immun; 2006 Feb; 74(2):968-74. PubMed ID: 16428742
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An immunohistological evaluation of Pseudomonas aeruginosa pulmonary infection in two patients with cystic fibrosis.
    Speert DP; Dimmick JE; Pier GB; Saunders JM; Hancock RE; Kelly N
    Pediatr Res; 1987 Dec; 22(6):743-7. PubMed ID: 3431961
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Pseudomonas aeruginosa outer membrane protein I vaccine: immunogenicity and safe administration in man.
    von Specht BU; Lücking HC; Blum B; Schmitt A; Hungerer KD; Domdey H
    Behring Inst Mitt; 1997 Feb; (98):326-37. PubMed ID: 9382756
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.
    Moore R; Kyd JM; Carzino R; Armstrong D; Grimwood K; Otczyk DC; Cripps AW
    Hum Vaccin Immunother; 2013 Mar; 9(3):506-14. PubMed ID: 23249482
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunization with a Pseudomonas aeruginosa elastase peptide reduces severity of experimental lung infections due to P. aeruginosa Or Burkholderia cepacia.
    Sokol PA; Kooi C; Hodges RS; Cachia P; Woods DE
    J Infect Dis; 2000 May; 181(5):1682-92. PubMed ID: 10823769
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IgG subclasses and chronic bacterial infection. Subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Pressler T
    APMIS Suppl; 1996; 66():1-41. PubMed ID: 8972694
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.